1) Van Vliet HAAM, et al:Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2011;2011:CD003553.
2) Kashanian M, et al:A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction:a study in Iran. Eur J Obstet Gynecol Reprod Biol 2010;150:47-51.
3) Kulier R, et al:Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reprod Health 2004;1:1.
4) European Medicines Agency:Benefits of combined hormonal contraceptives(CHCs)continue to outweigh risks. 2014. https://www.ema.europa.eu/en/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweighrisks_en.pdf
5) Stegeman BH, et al:Different combined oral contraceptives and the risk of venous thrombosis:systematic review and network meta-analysis. BMJ 2013;347:f5298.
6) Trivedi MK, et al:A Review of hormone-based therapies to treat adult acne vulgaris in women. Int J Womens Dermatol 2017;3:44-52.
7) Leblanc ES, et al:Benefits and risks of third-generation oral contraceptives. J Gen Intern Med 1999;14:625-632.
8) Arowojolu AO, et al:Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012;(7):CD004425.
9) Amiri M, et al:A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome:a crossover randomized controlled trial. Hum Reprod 2020;35:175-186.
10) Teede HJ, et al:Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clinical Endocrinology(Oxf)2018;89:251-268.
11) Lopez LM, et al:Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012;(2):CD006586.
12) Lawrie TA, et al:Types of progestogens in combined oral contraception:effectiveness and side-effects. Cochrane Database Syst Rev 2011;(5):CD004861.